Neoplasms, Plasma Cell: all 2,314 studies
Page 3 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingNCT05055063Phase 1
- Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with IsatuximabRecruitingNCT05053607Not applicable
- Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple MyelomaRecruitingNCT05007418Phase 1
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT04942067Phase 1/2
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
- Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT04879043Phase 1/2
- ATG-010(Selinexor) in Combination With Chemotherapy in RRMMRecruitingNCT04877275Phase 2
- Double Filtration Plasmapheresis Combined With ChemotherapyRecruitingNCT04836871Phase 1
- A Diagnostic Study of CD38-Targeted ImmunoPET of MyelomaRecruitingNCT04814615Phase 2
- A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04776330Phase 1/2
- CXCR4 Modified Anti-BCMA CAR T Cells for Multiple MyelomaRecruitingNCT04727008Phase 1
- Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT04714827Phase 1/2
- A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaNot yet recruitingNCT04670055Early Phase 1
- Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell TumorsRecruitingNCT04665076Not applicable
- T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple MyelomaRecruitingNCT04662099Phase 1
- APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaRecruitingNCT04657861Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple MyelomaRecruitingNCT04558931Phase 2
- A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells TherapyNot yet recruitingNCT04541368Early Phase 1
- Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.RecruitingNCT04533217Not applicable
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)RecruitingNCT04349358Not applicable
- BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell DiseaseRecruitingNCT04271644Phase 1/2
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentRecruitingNCT04268199Phase 2
- Autologous Stem Cell Transplantation for Patients With AL AmyloidosisEnrolling by invitationNCT04210791
- Multiple Myeloma Turkish Prospective Patient RegistryRecruitingNCT04143932
- Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma PatientsRecruitingNCT04025450Phase 1/2
- Fluciclovine PET/CT in Multiple Myeloma PatientsRecruitingNCT03966443
- Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma PatientsRecruitingNCT03832127Phase 1
- A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)Enrolling by invitationNCT03815279Phase 2
- MYeloma Resistance And Clonal EvolutionRecruitingNCT03807128
- Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple MyelomaAvailableNCT03763370
- CURATE.AI Optimized Modulation for Multiple MyelomaRecruitingNCT03759093Phase 2/3
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT03702309
- VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
- Pilot Imaging Study of LeukemiaRecruitingNCT03633955Phase 1
- The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)RecruitingNCT03562169Phase 3
- Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple MyelomaRecruitingNCT03490084
- Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple MyelomaRecruitingNCT03196414Phase 1/2
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
- Institut Paoli Calmettes Multiple Myeloma DatabaseRecruitingNCT02869555
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory MyelomaRecruitingNCT00800059Phase 1/2
- Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell TransplantsRecruitingNCT00106925
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
- A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USCompletedNCT06504524Results posted
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMMTerminatedNCT06160609Phase 1/2Results posted
- Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT05986682Results posted
- A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple MyelomaCompletedNCT05932290Results posted
- COVID19 OutcomeS in Myeloma and the Impact of VaCcinesCompletedNCT05831787Results posted
- A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaCompletedNCT05565391Results posted
- T-cell Receptor α/β Depleted Donor Lymphocyte InfusionTerminatedNCT05350163Phase 1Results posted
- A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple MyelomaCompletedNCT05347485Phase 2Results posted
- Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell TransplantCompletedNCT05274763Not applicableResults posted
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Phase 2Results posted
- Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesTerminatedNCT05191472Phase 2Results posted
- A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell LymphomaTerminatedNCT05121103Phase 1Results posted
- Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05117008Phase 2Results posted
- Removing Transfusion Dependence as a Barrier to Hospice EnrollmentCompletedNCT05063591Not applicableResults posted
- Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple MyelomaCompletedNCT04999085Not applicableResults posted
- Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT04896658Phase 1/2Results posted
- Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT04892446Phase 2Results posted
- Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
- Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyTerminatedNCT04816526Phase 2Results posted
- MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple MyelomaCompletedNCT04798586Phase 1Results posted
- A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)TerminatedNCT04776018Phase 1/2Results posted
- Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma PatientsTerminatedNCT04770402Not applicableResults posted
- A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
- Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)CompletedNCT04682405Phase 2Results posted
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbCompletedNCT04649359Phase 2Results posted
- Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaTerminatedNCT04649060Phase 3Results posted
- Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaTerminatedNCT04635735Phase 1/2Results posted
- Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving ChemotherapyTerminatedNCT04465760Phase 2Results posted
- Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
- Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
- Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyCompletedNCT04436029Phase 2Results posted
- A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT04434469Phase 1Results posted
- Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With DaratumumabTerminatedNCT04407442Phase 2Results posted
- A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)TerminatedNCT04272775Phase 1Results posted
- Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple MyelomaTerminatedNCT04205240Phase 2Results posted
- A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04177823Phase 1Results posted
- Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple MyelomaCompletedNCT04151667Phase 2Results posted
- Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaTerminatedNCT04119336Phase 2Results posted
- Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple MyelomaTerminatedNCT04097301Phase 1/2Results posted
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell DisordersCompletedNCT04080531Phase 4Results posted
- First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With DexamethasoneTerminatedNCT04075721Phase 1Results posted
- Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT03994705Phase 1Results posted
- T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaCompletedNCT03958656Phase 1Results posted
- sdAb-based TRNT of Multiple Myeloma: a Feasibility StudyCompletedNCT03956615Not applicableResults posted
- The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone LossCompletedNCT03951220Results posted
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Phase 2Results posted
- Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialCompletedNCT03941860Phase 3Results posted
- Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple MyelomaTerminatedNCT03910439Phase 2Results posted
- A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)TerminatedNCT03875495Phase 1/2Results posted
- Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With DaratumumabTerminatedNCT03871829Phase 2Results posted
- PROactive Evaluation of Function to Avoid CardioToxicityTerminatedNCT03862131Phase 2Results posted
- A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted